Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Humacyte Inc (HUMAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: HUMAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -40.94% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2 | 52 Weeks Range 0.17 - 3.47 | Updated Date 05/15/2025 |
52 Weeks Range 0.17 - 3.47 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4484.33% |
Management Effectiveness
Return on Assets (TTM) -42.82% | Return on Equity (TTM) -249.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 121934248 |
Shares Outstanding - | Shares Floating 121934248 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Humacyte Inc
Company Overview
History and Background
Humacyte Inc. is a biotechnology company focused on developing and manufacturing off-the-shelf, universally implantable bioengineered human tissues for a variety of potential applications. Founded in 2004, the company has focused on developing its Human Acellular Vessel (HAV) technology platform.
Core Business Areas
- Human Acellular Vessel (HAV): Humacyte's primary focus is on developing and commercializing HAVs for vascular repair, reconstruction, and replacement. Their HAVs are designed to provide a readily available alternative to autologous vessels, addressing unmet needs in vascular surgery and other clinical applications.
- Future Tissue Engineering: Humacyte is investing in future applications of its technology beyond HAVs, including potentially treating diseases and conditions in a variety of therapeutic areas.
Leadership and Structure
Laura Niklason, M.D., Ph.D. is the CEO of Humacyte. The organizational structure includes departments focused on research and development, manufacturing, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- Human Acellular Vessel (HAV) for AV Access: Humacyte's HAV is designed as a bypass graft for patients with end-stage renal disease requiring hemodialysis. Market share data is not readily available as the product is still in clinical development and not yet commercially available in major markets. Competitors include Gore (W. L. Gore & Associates) who provide ePTFE grafts and various pharmaceutical interventions to prevent graft failure.
- HAV for Peripheral Arterial Disease (PAD): Humacyte is also developing the HAV for use in PAD patients requiring lower extremity bypass. Market share data is not readily available as the product is still in clinical development. Competitors include synthetic grafts and autologous vein grafts.
Market Dynamics
Industry Overview
The regenerative medicine and tissue engineering industry is rapidly growing, driven by increasing demand for advanced therapies to address chronic diseases and unmet medical needs. Advancements in biomaterials, cell therapies, and tissue engineering technologies are fueling market expansion.
Positioning
Humacyte is positioned as a leader in developing off-the-shelf, bioengineered human tissues. The company's HAV technology platform has the potential to disrupt the vascular graft market by offering a readily available alternative to autologous vessels.
Total Addressable Market (TAM)
The total addressable market for vascular grafts is estimated to be several billion dollars annually. Humacyte is targeting a portion of this market by offering a superior alternative to existing solutions.
Upturn SWOT Analysis
Strengths
- Proprietary HAV technology platform
- Potential to address unmet needs in vascular surgery
- Off-the-shelf availability
- Experienced leadership team
Weaknesses
- Product still in clinical development
- Dependence on regulatory approvals
- Limited commercialization experience
- Cash Burn Rate
Opportunities
- Expansion into new indications (e.g., coronary artery bypass)
- Partnerships with pharmaceutical companies
- Geographic expansion
- Acquisition by larger medical device company
Threats
- Regulatory hurdles
- Competition from established medical device companies
- Technological advancements by competitors
- Unsuccessful clinical trials
Competitors and Market Share
Key Competitors
- GORE
- BSX
- JNJ
Competitive Landscape
Humacyte has a unique technology that could disrupt the vascular graft market. However, it faces competition from established medical device companies with greater financial resources and commercialization expertise.
Growth Trajectory and Initiatives
Historical Growth: Humacyte's historical growth has been focused on advancing its HAV technology through preclinical and clinical studies.
Future Projections: Future growth depends on the successful completion of clinical trials, regulatory approvals, and commercialization of the HAV product. Analyst estimates vary widely, reflecting the uncertainty associated with these milestones.
Recent Initiatives: Recent initiatives include enrollment and ongoing clinical trials for AV access and PAD, and exploring new applications for the HAV technology.
Summary
Humacyte is a high-risk, high-reward biotechnology company focused on its HAV technology. While the technology holds promise for addressing unmet needs in vascular surgery, the company faces significant challenges related to clinical development, regulatory approvals, and commercialization. Success hinges on positive clinical trial outcomes and navigating the competitive landscape. The recent dilutive financing has also put a burden on the stock.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Humacyte Inc. SEC Filings
- Analyst reports
- Company website
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Humacyte Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2020-11-24 | Founder, President, CEO & Director Dr. Laura E. Niklason M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 218 | Website https://humacyte.com |
Full time employees 218 | Website https://humacyte.com | ||
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.